Nutritional biomarkers in Alzheimer's disease: the association between carotenoids, n-3 fatty acids, and dementia severity.
Study Design
- Loại nghiên cứu
- Other
- Đối tượng nghiên cứu
- None
- Can thiệp
- Nutritional biomarkers in Alzheimer's disease: the association between carotenoids, n-3 fatty acids, and dementia severity. None
- Đối chứng
- None
- Kết quả chính
- Nutritional biomarkers in Alzheimer's disease: the association between carotenoi
- Xu hướng hiệu quả
- Mixed
- Nguy cơ sai lệch
- Moderate
Abstract
Carotenoids are fat-soluble antioxidants that may protect polyunsaturated fatty acids, such as n-3 fatty acids from oxidation, and are potentially important for Alzheimer's disease (AD) prevention and treatment. Fasting plasma carotenoids were measured in 36 AD subjects and 10 control subjects by HPLC. Correlations between plasma carotenoid levels, red blood cell (RBC) n-3 fatty acids, and dementia severity were examined in AD patients. Moderately severe AD patients (MMSE=16-19) had much lower plasma levels of two major carotenoids: lutein and beta-carotene, compared to mild AD patients (MMSE=24-27) or controls. Among AD patients, variables (lutein, beta-carotene, RBC docosahexaenoic acid (DHA) and LDL-cholesterol) were significantly correlated with MMSE. A lower MMSE score was associated with lower lutein, beta-carotene and RBC DHA levels, and a higher LDL-cholesterol level. These variables explained the majority of variation in dementia severity (55% of variance in MMSE). Lutein, beta-carotene and beta-cryptoxanthin were positively correlated with RBC DHA in AD patients. The association between higher carotenoids levels and DHA and higher MMSE scores, supports a protective role of both types of nutrients in AD. These findings suggest targeting multiple specific nutrients, lutein, beta-carotene, and DHA in strategies to slow the rate of cognitive decline.
Tóm lược
The association between higher carotenoids levels and DHA and higher MMSE scores, supports a protective role of both types of nutrients in AD and suggest targeting multiple specific nutrients, lutein, beta-carotene, and DHA in strategies to slow the rate of cognitive decline.
Used In Evidence Reviews
Similar Papers
Pharmacological research · 1999
Health benefits of docosahexaenoic acid (DHA).
Circulation · 2010
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.
Contemporary clinical trials · 2012
The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.
Journal of clinical hypertension (Greenwich, Conn.) · 2011
Role of mercury toxicity in hypertension, cardiovascular disease, and stroke.
Progress in neuro-psychopharmacology & biological psychiatry · 2008
The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
The Cochrane database of systematic reviews · 2007